Wednesday, October 8, 2025

Latest

Phage Therapy’s Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy as a potentially revolutionary biotech solution. He illustrates its efficacy by citing a successful treatment of a severe infection in Ottawa, underscoring the increasing demand for alternative treatments to combat antibiotic resistance.

Dr. Theriault outlines Cytophage’s expansion strategy, focusing on South Asia with a new product launch in Bangladesh and partnerships with major poultry integrators. He also touches on the development of phage-based vaccines and the company’s focus on both animal and human applications.

Looking ahead, Dr. Theriault highlights Cytophage’s goals: revenue generation, advancement of human clinical trials, and formation of strategic partnerships. These reflect the company’s ambition to capitalize on the growing interest in phage therapy.


FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

McDonald’s E.coli Crisis: This Canadian Biotech May Have The Solution | Cytophage with Steven Theriault

In this interview, Dr. Steven Theriault, CEO & Chief Science Officer of Cytophage Technologies (TSXV:...
Saturday, November 16, 2024, 09:13:00 AM

Cytophage Develops Freeze-Dried Phage Tablets For Poultry

Cytophage Technologies (TSXV: CYTO) has announced the launch of a new product that it believes...
Thursday, August 15, 2024, 02:56:00 PM

Cytophage Reports Early Success In Single Subject Clinical Trial

Cytophage Technologies (TSXV: CYTO) has seen early success in a recently completed human trial conducted...
Tuesday, April 2, 2024, 09:05:42 AM

Cytophage To Focus On Commercialization Efforts In 2024

Cytophage Technologies (TSXV: CYTO) has filed its fiscal 2023 results, providing a recap on a...
Tuesday, April 30, 2024, 10:13:02 AM

Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company

Cytophage Technologies (TSXV: CYTO) is focusing its efforts on expanding the commercialization of its phage...
Friday, June 21, 2024, 08:45:08 AM